NIDDM and IR in Combination Therapy for CHC

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The influence of insulin sensitivity and glucose tolerance on the effects of antiviral therapy for HCV remains unclear. The aim of the present study was (1) To elucidate the clinical and virological factors associated with sustained viral response in patients with combination therapy with PEG-IFN and ribavirin. (2) To clarify the influence of diabetes mellitus (DM), impaired glucose tolerance test (IGT) and insulin resistance (IR) on the HCV response to combination therapy with PEG-IFN and ribavirin. (3) To test the influence of combination therapy on HOMA IR

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
• Collaborator: National Science Council, Taiwan
• Treatments: Interferon-alpha; Interferons; Ribavirin

Criteria

Inclusion Criteria:

1. Chronic hepatitis C patients with positive anti-HCV for more than 6 months and HCV RNA

2. No overt hepatic failure or decompensated liver cirrhosis (Child-Pugh class B or C) or hepatocellular carcinoma.

Exclusion Criteria:

1. Positive for hepatitis B surface antigen (HBsAg)or with concomitant human immunodeficiency virus infection

2. With other types of hepatitis including autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, Wilson's disease, alpha 1-antitrypsin deficiency

3. Current or past history of alcohol abuse (80 mL ethanol per day)